I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in BarcelonaROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be he ...